This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc., a leading global pharmaceutical company, is headquartered in the United States and operates extensively across North America. Founded in 1901, Teva has established itself as a key player in the pharmaceutical industry, focusing on generic and specialty medications. The company is renowned for its diverse portfolio, which includes a wide range of therapeutic areas such as central nervous system disorders, respiratory conditions, and oncology. Teva's commitment to innovation is evident in its development of unique formulations and delivery systems, setting it apart in a competitive market. With a strong market position, Teva has achieved notable milestones, including being one of the largest generic drug manufacturers worldwide. The company's dedication to improving patient access to essential medications underscores its pivotal role in the healthcare landscape.
DitchCarbon Score
How does Teva Pharmaceuticals USA, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Pharmaceuticals USA, Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Teva Pharmaceuticals USA, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Teva Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. Teva Pharmaceutical Industries Limited, as the parent organisation, has set various climate initiatives and targets that cascade down to Teva Pharmaceuticals USA, Inc. These initiatives include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which aim to enhance transparency and accountability in emissions reduction efforts. However, specific reduction targets or achievements for Teva Pharmaceuticals USA, Inc. have not been disclosed. As part of its commitment to sustainability, Teva Pharmaceuticals USA, Inc. aligns with broader industry standards and practices, although detailed metrics on emissions or specific reduction goals are not currently available. The absence of direct emissions data highlights the need for ongoing efforts in climate accountability and transparency within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva Pharmaceuticals USA, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
